Targets › OCN19
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2028.
Open in Phaseline: the race on OCN19, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Lu jin ,MD | mesenchymal stem cells with OCN-19 OCN19-overexpressed mesenchymal stem cells that stimulate insulin gene expression and isle | OCN19 | Phase 2 | Diabetes | Dec 2028 |
Diabetes (1)
mixed (1)
Lu jin ,MD (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.